MCAS, EDS, and POTS: The Trifecta Nobody Talks About

If you’ve been diagnosed with one of these conditions, there’s a real chance the other two are hiding in plain sight.

You’ ve been to seven doctors. You’ ve been told it’ s anxiety. You’ ve been told it’ s “just stress.” Your labs look normal, but nothing about your body feels normal. You flush for no reason. Your heart races when you stand up. Your joints pop and ache. Your gut is a daily guessing game. You react to foods that never bothered you before. And every specialist you see only looks at their piece of the puzzle.

If this sounds like your life, you may be dealing with something the medical world is only now beginning to take seriously: The Trifecta — the co–occurrence of Mast Cell Activation Syndrome (MCAS), Hypermobile Ehlers–Danlos Syndrome (hEDS), and Postural Orthostatic Tachycardia Syndrome (POTS).

These three conditions appear together at rates that far exceed statistical chance, particularly in young women. And the common thread weaving them together? Histamine.

What Are These Three Conditions?

Before we explain how they connect, let’ s briefly define each one.

Mast Cell Activation Syndrome (MCAS)

MCAS is a condition in which mast cells — immune cells found throughout your body — become overactive and release excessive amounts of chemical mediators, especially histamine. This leads to unpredictable, episodic symptoms across multiple body systems: flushing, hives, brain fog, digestive distress, rapid heart rate, and sometimes anaphylaxis. Unlike typical allergies, MCAS reactions can be triggered by stress, temperature changes, fragrances, and foods — not just allergens.

For a deeper dive, read our full article: What is Mast Cell Activation Syndrome?

Hypermobile Ehlers–Danlos Syndrome (hEDS)

hEDS is a connective tissue disorder caused by defective collagen organization. Collagen is the most abundant protein in the body — it gives structure to skin, joints, blood vessels, organs, and the gut lining. When collagen doesn’ t form properly, the result is overly lax, fragile connective tissue throughout the body. This manifests as joint hypermobility, chronic pain, easy bruising, stretchy skin, and a host of seemingly unrelated symptoms that span every organ system.

hEDS is the most common type of Ehlers-Danlos Syndrome, accounting for 80–90% of all EDS cases. There is no genetic test for it — diagnosis is entirely clinical.

Postural Orthostatic Tachycardia Syndrome (POTS)

POTS is a form of dysautonomia — a malfunction of the autonomic nervous system, which controls heart rate, blood pressure, digestion, and temperature regulation. In POTS, the heart rate increases excessively when you move from lying down to standing (an increase of 30 beats per minute or more within 10 minutes), causing symptoms like dizziness, lightheadedness, brain fog, palpitations, exercise intolerance, and fainting.

POTS affects an estimated 500,000 to 3 million people in the United States alone, and 80–85% of patients are female.

How Common Is the Trifecta?

The numbers are striking — and they keep growing as awareness improves.

The Landmark Study: 31% Overlap

A widely cited 2021 study from Tufts University School of Medicine examined 195 patients and found that 31% of patients with both POTS and hEDS also had MCAS, compared to only 2% of patients without POTS and EDS. The odds ratio was 32.46 — meaning if you have both POTS and hEDS, you are over 30 times more likely to also have MCAS.

One in Four: The Full Trifecta

A 2025 study published in Autonomic Neuroscience followed 84 women with physician–diagnosed hEDS or Hypermobility Spectrum Disorder (HSD) and found:

• 58.3% had POTS
• 32.1% had MCAS
• 25% had all three diagnoses simultaneously — one in four

These patients also had a quality of life worse than people with multiple sclerosis, rheumatoid arthritis, and lupus. Nearly 99% reported chronic pain.

More Numbers That Matter

• People with hEDS are 29.7 times more likely to be diagnosed with POTS than the general population
• An analysis of over 37,000 patients found that nearly 1 in 3 patients diagnosed with MCAS had a comorbid hEDS diagnosis
• 38% of EDS patients met criteria for POTS; among those under 25, the rate climbed to 72%
• 42% of POTS patients with allergic or gastrointestinal symptoms showed mast cell mediator abnormalities

Why Do MCAS, EDS, and POTS Travel Together?

This isn’ t a coincidence. There are well-described biological mechanisms that explain why defective connective tissue can trigger both mast cell overactivation and autonomic dysfunction — and why histamine sits at the centre of all three.

Step 1: Defective Collagen Is the Foundation

In hEDS, the collagen that provides structural integrity to tissues throughout the body is disorganized and overly compliant. This single underlying defect ripples outward, affecting blood vessels, nerves, the gut lining, and the extracellular matrix (ECM) where mast cells reside.

Think of it this way: collagen is the scaffolding your body is built on. When the scaffolding is too loose, everything it supports becomes unstable.

Step 2: Loose Connective Tissue Triggers Mast Cells

Here’ s where it gets fascinating. Mast cells don’ t just float around — they’ re embedded in connective tissue. And they are exquisitely sensitive to the physical properties of the tissue around them.

A 2022 study published in Frontiers in Cell and Developmental Biology revealed the mechanobiological mechanism:

• In normal connective tissue, a stiff, well–organized collagen matrix keeps mast cells stable. A protein called vimentin forms a “cage“ around the mast cell‘ s secretory granules, preventing inappropriate degranulation.
• In hEDS connective tissue, the abnormally soft, loose extracellular matrix disrupts vimentin organization. The granule “cages” weaken. Physical vibrations and strain are amplified through the soft tissue.
• The result: mast cells in hEDS tissue are structurally primed to degranulate more easily — releasing histamine and other inflammatory mediators at lower thresholds.

In other words, the very tissue that houses your mast cells is telling them to overreact.

Step 3: Loose Blood Vessels Cause POTS

Blood vessels — especially the veins in your legs — rely on strong connective tissue to constrict properly when you stand. In hEDS:

1. 1.Vein walls are too compliant and fail to constrict adequately
2. 2.Blood pools in the lower extremities instead of returning to the heart
3. 3.The heart compensates by racing — this is the tachycardia in POTS
4. 4.The sympathetic nervous system kicks into overdrive to maintain blood pressure

This process, described in Frontiers in Neurology, also explains why POTS is among the most disruptive comorbidities in hEDS — with up to 40% of hEDS patients experiencing some form of orthostatic intolerance.

Histamine. The Thread That Ties the Trifecta Together

If you follow The Histamine Code, you already know that histamine isn’ t just about allergies

— it’ s a powerful signalling molecule with effects across nearly every system in the body. In the trifecta, histamine acts as both a trigger and an amplifier.

Histamine Drives POTS Symptoms

Histamine is one of the most potent vasodilators in the body. When mast cells degranulate and flood the system with histamine:

1. Blood vessels dilate — worsening the pooling already caused by lax connective tissue
2. Venous return drops further — less blood reaches the heart and brain
3. Heart rate climbs higher — the compensatory tachycardia that defines POTS intensifies
4. The sympathetic nervous system fires harder — releasing norepinephrine and substance P

And here‘ s the cruel twist: norepinephrine and substance P act directly on mast cells, triggering more degranulation and more histamine release. It becomes a self–reinforcing positive feedback loop.

This is particularly relevant in the hyperadrenergic subtype of POTS, where the sympathetic nervous system is in a state of chronic overdrive. A case study published in the Journal of Hypertension demonstrated complete remission of hyperadrenergic POTS using histamine blockers alone — illustrating how histamine can be the primary driver in some POTS patients.

Histamine Fuels Neuroinflammation

Histamine isn‘ t just a peripheral player. It‘ s an active neuromodulator in the central nervous system, influencing wakefulness, attention, memory, and cognitive function. When histamine levels are chronically elevated:

• Brain fog worsens
• Sleep is disrupted (histamine is a wakefulness chemical)
• Anxiety and mood disturbances increase
• Pain sensitivity heightens through central sensitization

There’ s also a bidirectional nerve-mast cell communication loop: sensory nerve endings release neuropeptides like substance P and CGRP, which trigger mast cell degranulation. The mast cells release histamine, which activates more nerve endings. This neurogenic inflammation cycle helps explain the widespread pain and neurological symptoms that trifecta patients experience.

Histamine and the Gut–Brain–Immune Axis

Mast cells line the digestive tract in large numbers and sit in close proximity to autonomic nerve endings. When these mast cells activate, they trigger signals along the gut-brain axis — contributing to the gastroparesis, IBS-like symptoms, and dysmotility that affect up to 76% of hEDS patients who undergo motility testing.

Add to this the role of diamine oxidase (DAO) — the enzyme that breaks down dietary histamine in the gut. When DAO activity is low, histamine from food accumulates, raising the total body burden. A 2026 study in Frontiers in Pain Research found DAO deficiency–associated genetic variants in 74.5% of fibromyalgia patients and showed that DAO supplementation significantly reduced pain and functional impairment in a randomized controlled trial. Since fibromyalgia frequently co–occurs with hEDS, this histamine–DAO connection may represent an overlooked and treatable contributor to pain in the trifecta.

Why the Trifecta Gets Missed: A Diagnostic Disaster

If the overlap is so well-documented, why does it take so long to get diagnosed?

The short answer: medicine is structured to look at one organ at a time. The trifecta doesn’ t cooperate.

The Numbers Are Sobering

For hEDS:

• Average time to diagnosis: over 10 y ears, with more than 15 doctor visits
• Half of patients waited over 14 years ; a quarter waited up to 28 years
• Women waited an average of 16 years, compared to 4 years for men
• A 2025 study of 429 hEDS patients found that 94.4% were previously misdiagnosed with a psychiatric condition — 88% were told they were “making it up” and 76% were labeled attention–seeking

For POTS:

• Average diagnostic delay: approximately 5 y ears, seeing an average of 7 doctors
• 69% were diagnosed with an anxiety disorder before receiving their POTS diagnosis
• 59% were told their symptoms were “all in their head“
• 34% of patients ultimately suggest the diagnosis themselves after doing their own research For MCAS:
• No standardized data exists on diagnostic delay, but MCAS is widely considered underdiagnosed
• Challenges include disagreement over diagnostic criteria, limited availability of urinary mediator testing, and most standard allergy labs appearing normal

Why Doctors Miss It

1. Siloed specialties: hEDS is diagnosed by rheumatologists or geneticists ; POTS by cardiologists or neurologists ; MCAS by allergists. Each specialist often evaluates only their own domain.
2. Normal–looking tests: Standard labs, EKGs, and imaging are typically unremarkable. Diagnosis requires specific functional testing — Beighton scoring, tilt table tests, timed tryptase draws during episodes.
3. Gender bias: With 80–85% of POTS patients and the majority of hEDS patients being female, these patients are disproportionately dismissed as anxious.
4. No medical school training : Autonomic disorders including POTS are not meaningfully covered in most medical school curricula.
5. The MCAS controversy: Clinicians disagree about how to diagnose MCAS. The strict consensus criteria require tryptase elevation during a flare — a test that is logistically dificult to obtain and may be normal in some MCAS patients. Broader clinical criteria capture more patients but remain debated.

As Dr. Dacre Knight, Medical Director of the UVA Health EDS and Hypermobility Disorders Center, has described: when diagnosis is delayed, complexity isn‘ t inevitable — it‘ s created.

The Good News: Treating One Can Help All Three

Because these conditions are biologically interconnected, treating one condition often improves the others. This is especially true when histamine is addressed as a central driver.

Antihistamines for MCAS — And POTS

Combined H1 and H2 antihistamine therapy (e.g., cetirizine + famotidine) is now included in POTS management guidelines when MCAS co-exists. By blocking histamine’ s vasodilatory effects, antihistamines can reduce blood pooling, lower compensatory tachycardia, and improve orthostatic tolerance.

A 2025 study in Frontiers in Neurology found that 82% of POTS patients who received MCAS–targeted therapy responded positively at an average follow–up of 33 months — including many who did not meet strict laboratory criteria for MCAS. The therapies included H1/H2 blockers, mast cell stabilizers, leukotriene inhibitors, cromolyn sodium, low–dose naltrexone, DAO supplementation, and omalizumab.

Mast Cell Stabilizers

Cromolyn sodium and ketotifen prevent mast cell degranulation before it happens. These are particularly helpful for GI symptoms and for reducing the total mediator burden that drives both MCAS and POTS symptoms.

Low–Histamine Diet and DAO Support

For patients whose POTS is driven by mast cell activation, reducing dietary histamine can directly reduce vasodilation triggers. The low-histamine diet eliminates aged cheeses, fermented foods, cured meats, alcohol, and leftover proteins — all sources of exogenous histamine that add to the body’ s total histamine load.

DAO enzyme supplementation before meals can help patients tolerate a wider variety of foods by supporting the breakdown of dietary histamine in the gut. This is especially relevant given the emerging evidence linking DAO deficiency to pain and fatigue in related conditions.

For a comprehensive food guide, see our Low Histamine Diet page.

Physical Therapy and Compression

Managing hEDS through targeted physical therapy — joint stabilization, muscle strengthening around lax joints — reduces physical microtrauma to connective tissue, which may reduce mechanical mast cell degranulation. Compression garments, prescribed for POTS, also improve venous return and reduce the sympathetic activation cascade that drives mast cell activity.

An important caveat: Standard graded exercise programs for POTS can trigger mast cell degranulation in MCAS patients. Exercise prescription should account for MCAS status — starting lower, progressing slower, and monitoring for post–exertional flares.

The Stepwise Approach

Clinicians experienced with the trifecta typically layer treatments in this order:

Priority	Target	Approach
1	Acute MCAS episodes	Epinephrine auto–injector if anaphylaxis; oral H1 antihistamine for milder episodes
2	MCAS prevention	Second–generation H1 antihistamine + H2 blocker (e.g., famotidine)
3	POTS hemodynamics	Fluid and salt loading, compression garments, graded reconditioning
4	POTS heart rate	Beta–blockers, ivabradine, or pyridostigmine
5	MCAS escalation	Leukotriene modifiers, oral cromolyn, ketotifen, aspirin (if tolerated)
6	hEDS musculoskeletal	Targeted physical therapy, joint stabilization, pain management
7	Refractory MCAS	Omalizumab, low–dose naltrexone, short–term corticosteroids

Source: Canadian MCAS Review (2025); Standing Up to POTS

A Note on the Diagnostic Debate

We believe in transparency. The MCAS component of the trifecta is the most debated in the medical literature. The strict ECNM–AIM consensus criteria require documented tryptase elevation during flares — a logistically challenging test that is normal in many patients who still benefit from mast cell–targeted treatment. A 2025 systematic review found that no studies to date have confirmed the trifecta using the strictest diagnostic criteria simultaneously applied to all three conditions.

But here‘ s what matters clinically: the Yao et al. 2025 study showed that 82% of POTS patients improved on mast cell–targeted therapy — regardless of whether they met formal MCAS laboratory criteria. Functional mast cell involvement appears to be common in POTS, and treating it can make a meaningful difference in people‘ s lives.

The absence of a confirmed MCAS diagnosis does not rule out benefit from a histamine-lowering approach. If your symptoms point to mast cell involvement, talk to a knowledgeable provider about whether a therapeutic trial is appropriate for you.

When to Suspect the Trifecta

Consider whether the trifecta might apply to you if you experience:

• Joint hypermobility — you‘ ve always been “ bendy” or “double–jointed,” with frequent sprains, subluxations, or chronic joint pain
• Orthostatic symptoms — dizziness, racing heart, brain fog, or near–fainting when standing up
• Multi–system mast cell symptoms — unexplained flushing, hives, food reactions, GI distress, headaches, or skin sensitivity
• A long medical history with many diagnoses (IBS, anxiety, fibromyalgia, chronic fatigue) but no unifying explanation
• Symptoms that worsen with heat, stress, menstrual cycles, or certain foods
• Being told repeatedly that “everything looks normal“

If this resonates, you don’ t have to wait another 10 years for answers. Bring this conversation to a provider who understands these conditions — or reach out to us.

The Bottom Line

MCAS, hEDS, and POTS are not three separate problems that happen to show up together. They are biologically connected through defective connective tissue, dysregulated mast cells, and the cascade of histamine that links them all. Understanding the trifecta changes everything — from how you interpret your symptoms to how you and your provider approach treatment.

And at the centre of it all is histamine: the molecule that makes mast cells fire, blood vessels dilate, hearts race, guts rebel, and brains fog. Addressing histamine — through diet, DAO

support, antihistamines, and mast cell stabilizers — is often the single most impactful intervention for trifecta patients.

If you’ ve been searching for the missing piece — the thing that explains why everything seems connected — histamine might just be the answer you’ ve been looking for.

If you‘re living with MCAS, histamine intolerance, or suspect the trifecta, we‘re here to help. Book a consultation with Dr. Bobby Parmar or Dr. Krista Moyer, or explore our resources on diagnosis, treatment, and the low–histamine diet.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualiied healthcare provider for diagnosis and treatment.